4.7 Article

Clinical outcomes in COVID-19 patients infected with different SARS-CoV-2 variants in Marseille, France

Journal

CLINICAL MICROBIOLOGY AND INFECTION
Volume 27, Issue 10, Pages -

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.cmi.2021.05.029

Keywords

Coronavirus disease 2019; Marseille; Mutation; N501Y; Severe acute respiratory syndrome; coronavirus 2; Variant

Funding

  1. Institut Hospitalo-Universitaire Mediterranee Infection
  2. French National Research Agency under the Investissements d'avenir programme [ANR-10-IAHU-03]
  3. Region Provence Alpes Cote d'Azur
  4. European FEDER PRIMI fund

Ask authors/readers for more resources

The study compared the clinical and epidemiological aspects associated with different predominant lineages circulating in Marseille from March 2020 to January 2021. The four lineages presented differences in epidemiological and clinical characteristics, supporting the use of genomic surveillance for SARS-CoV-2 through next-generation sequencing.
Objectives: To compare the clinical and epidemiological aspects associated with different predominant lineages circulating in Marseille from March 2020 to January 2021. Methods: In this single-centre retrospective cohort study, characteristics of patients infected with four different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants were documented from medical files. The outcome was the occurrence of clinical failure, defined as hospitalization (for outpatients), transfer to the intensive care unit (inpatients) and death (all). Results: A total of 254 patients were infected with clade 20A (20AS), 85 with Marseille-1 (M1V), 190 with Marseille-4 (M4V) and 211 with N501Y (N501YV) variants. 20AS presented a bell-shaped epidemiological curve and nearly disappeared around May 2020. M1V reached a very weak peak, then disappeared after six weeks. M4V appeared in July presented an atypical wave form for 7 months. N501YV has only recently appeared. Compared with 20AS, patients infected with M1V were less likely to report dyspnoea (adjusted odds ratio (OR) 0.50, p 0.04), rhinitis (aOR 0.57, p 0.04) and to be hospitalized (aOR 0.22, p 0.002). Patients infected with M4V were more likely to report fever than those with 20AS and M1V (aOR 2.49, p < 0.0001 and aOR 2.30, p 0.007, respectively) and to be hospitalized than those with M1V (aOR 4.81, p 0.003). Patients infected with N501YV reported lower rate of rhinitis (aOR 0.50, p 0.001) and anosmia (aOR 0.57, p 0.02), compared with those infected with 20AS. A lower rate of hospitalization was associated with N501YV infection compared with 20AS and M4V (aOR 0.33, p < 0.0001 and aOR 0.27, p < 0.0001, respectively). Conclusions: The four lineages have presentations that differ from one another, epidemiologically and clinically. This supports SARS-CoV-2 genomic surveillance through next-generation sequencing. (C) 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available